Antiproliferative Potential of Pomegranate Peel Extract in MDA-MB Breast Cancer Cell Lines

Nutraceuticals have gained recognition as adjuvant therapies in cancer treatment due to their non-toxic and protective properties. Among various natural products, pomegranate peel with high antioxidant capacity and rich polyphenol content suggest potential anticancer properties. Previous studies have shown promising anticancer effects of other parts of the pomegranate. The purpose of this research is to compare the effectiveness of Pomegranate Peel Extract (PPE) on triple-negative breast cancer with that of oestrogen receptor-positive breast cancer. We assessed PPE's anticancer potential using MTT, Superoxide Dismutase (SOD) activity and Glutathione Peroxidase (GPX) on the MDA-MB-231 and MCF-7 cell lines for breast cancer. Initial cytotoxicity assays demonstrated favourable results in both cell lines, prompting further evaluation of antioxidant activity, particularly in MDA-MB-231. The cytotoxicity tests showed positive results following PPE treatment in the MDA-MB-231 and MCF-7 breast cancer cell lines. Following these initial results, the SOD and GPX assays revealed a significant antioxidant activity in the MDA-MB-231 cell line, indicating PPE's potential role in reducing oxidative stress in these cells. These results suggest that PPE exhibits anticancer activity and antioxidant properties that may be beneficial in targeting difficult-to-treat breast cancers, particularly MDA-MB-231. According to the study's findings, PPE shows promise as an antioxidant and anticancer agent, particularly when used to treat triple-negative breast cancer. The cytotoxicity, SOD activity and GPX assay results show promise for PPE as a preventive or adjuvant treatment for breast cancer. To completely comprehend its mechanics and therapeutic effects in clinical settings, further investigation is necessary.